Nanotherapeutics Hub joins iiCON to help strengthen UK’s infectious disease products pipeline

  02 June 2021

The Nanotherapeutics Hub will work with iiCON to support companies looking to develop nanotherapetuics to combat infectious diseases and access the nanomedicne market, which is expected to be worth $169 billion USD by 2026.

The Nanotherapeutics Hub will support companies by providing advanced analytical capabilities and expertise on biocompatibility, biodistribution and pharmacokinetics, physical and chemical characterisation, and the development of better models to improve therapeutic delivery to the biological target site whilst ensuring patient safety.

Led by the Liverpool School of Tropical Medicine (LSTM) and backed by UKRI’s Strength in Places Fund (SIPF), iiCON is aiming to strengthen the UK’s infectious diseases product pipeline. The consortium supports industry in bringing new game-changing therapeutics and products to market in response to the growing global threat of infectious diseases and antimicrobial resistance (AMR).

Author(s): European Pharmaceutical Manufacturer
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support kindly provided by

Antimicrobial Resistance Fighter Coalition

CDD VAULT Complexity Simplified





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!